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Both guidelines list leukotriene inhibitors as
a potential adjunct to corticosteroids for moder-
ate persistent asthma, as an alternative to cor-
ticosteroids plus long-acting beta2-agonist. The
guidelines also list leukotriene inhibitors as an
alternative treatment to inhaled corticosteroids
for mild persistent asthma in patients aged >5
years. Montelukast (Singulair) is approved for
use in children aged >12 months, zafirlukast
(Accolate) is approved for children aged >5
years, and zileuton (Zyflo) is approved only for
children aged >12 years.
Nancy E. Morden, MD, Department of Family Medicine,
University of Washington, Seattle; Leilani St. Anna,
MLIS, AHIP, University of Washington Health Sciences
Library, Seattle
■ CLINICAL COMMENTARY
An inhaled corticosteroid controller 
should be the first step
Until evidence supports a different conclu-
sion, I think we should continue to follow
current national and global guidelines. The
most important concept in both is that once a
child is diagnosed with persistent asthma,
starting an inhaled corticosteroid controller
should be the first step. 
Leukotriene inhibitors should be considered
as second or third choice as a controller. The
main indications for using a leukotriene
inhibitor are aspirin-sensitive, exercise-
induced, and nocturnal asthma. I would use a
leukotriene inhibitor as a controller only if a
patient could not comply with inhaled corti-
costeroids.
Lawrence S. Slotnick, MD, Moses Cone Health
System, Greensboro, NC
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■ EVIDENCE-BASED ANSWER 
No individual or combination of blood tests can reli-
ably diagnose pelvic inflammatory disease (PID)
(strength of recommendation [SOR]: A, meta-
analysis). The combination of white blood cell
count, C-reactive protein (CRP), erythrocyte sedi-
mentation rate (ESR), and vaginal white blood cells
can reliably exclude PID if results for all 4 tests are
normal (sensitivity=100%) (SOR: B, cohort study,
reference standard not uniformly applied). 
The combination of CRP and ESR is helpful in
excluding PID (sensitivity=91%) and may be
especially useful in distinguishing mild from com-
plicated cases (SOR: B, small cohort study).
Individual tests do not appear to significantly
improve diagnostic accuracy, although the CRP
and ESR are somewhat useful to rule out PID
(SOR: B, small cohort study).
■ EVIDENCE SUMMARY
Because of the significant inflammatory sequelae
of PID, it is the standard of care to treat women
with suggestive signs and symptoms. Clinical
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diagnosis has a positive predictive value of 65% to
90% compared with laparoscopy.1 While no single
test is both sensitive and specific, a combination
of biochemical tests for inflammation may
improve the ability to rule out PID.
A prospective cohort study of 120 women pre-
senting to an ambulatory center with symptoms of
PID evaluated the tests commonly used to sup-
port the clinical diagnosis of PID.2 The objective
criteria used for diagnosis included histologic evi-
dence of acute endometritis via endometrial biop-
sy, purulent exudates in the pelvis on laparoscopy,
or microbiologic evidence of Neisseris gonorrhea or
Chlamydia trachomatis from the upper genital
tract. The Table shows the sensitivities, specifici-
ties, and predictive values for an elevated white
blood cells (>10,000/mm), ESR (>15 mm/hr),
CRP (>5 mg/dL), and increased vaginal white
blood cells (>3 white blood cells/high-power field)
for detection of PID. If all 4 test results are nega-
tive, PID is reliably ruled out with a sensitivity of
100%. These results may be an overestimate, as
the gold standard was not uniformly applied. 
The role of CRP and ESR in the diagnosis of
acute PID was studied in 41 women with clinical-
ly suspected acute PID who presented to a uni-
versity department of obstetrics and gynecology.3
Women underwent laparoscopy, endometrial sam-
pling, and cultures of the upper genital tract to
confirm the diagnosis. When considered together,
a positive value in either the ESR (cutoff level of
15 mm/hr) or CRP (cutoff >20 mg/dL) had a sen-
sitivity of 91% and a specificity of 50%. 
Another report looked at the ability of ESR and
CRP to differentiate between mild, moderate, and
severe PID in 72 women undergoing laparoscopy
at a university department of gynecology.4 The
cutoff levels were ESR >40 mm/hr and CRP >60
Diagnostic performance of blood tests 
for pelvic inflammatory disease
Sn (%) Sp (%) PPV (%)* NPV (%)*
WBC (>10,000/mm3)2 57 88 88 58
ESR (>15 mm/hr)2 70 52 69 54
CRP (>5 mg/dL)2 71 66 76 60
Vaginal WBCs2 78 39 66 54
0 of 4 of the above 
positive2 100 18 100 65
4 of 4 of the above 
positive2 29 95 90 47
CRP >20 or ESR >153 91 50 N/A N/A
CRP >60 or ESR >404 97 61 70 96
CRP (metaanalysis)5 74%–93% 50%–90%
ESR (metaanalysis)5 64%–81% 43%–69%
*Prevalence=60%. SN, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; WBC, white blood
cells; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
TA B L E
C L I N I C A L  I N Q U I R I E S
APRIL 2004 / VOL 53, NO 4 · The Journal of Family Practice 331
mg/dL. If either test was abnormal, the sensitivi-
ty and the negative predictive value for severe dis-
ease were 97% and 96%, respectively (Table). All
patients with tuboovarian abscess or perihepatitis
and 6 of 7 patients who had anaerobic bacteria
isolated from the fallopian tubes tested positive
with these cutoff levels.
A meta-analysis from 1991 found 12 studies,
not including any of the above studies, and
assessed the laboratory criteria for the diagnosis
of PID. No single or combination diagnostic indi-
cator was found to reliably predict PID. However,
the CRP and the ESR were useful in ruling 
out PID, with good sensitivities for CRP in 4 of 
4 studies analyzed (74%–93%) and for the ESR in
4 of 6 studies (64%–81%). Ten of 12 studies used
laparoscopy as the gold standard.5
■ RECOMMENDATIONS FROM OTHERS
The Centers for Disease Control and Prevention
makes no specific recommendation for the use of
specific blood tests in the diagnosis of PID.1 The
Association for Genitourinary Medicine states
that an elevated ESR or CRP supports the diag-
nosis of PID.6
Mary N. Hall, MD, Laura Leach, MLIS, Carolinas
Healthcare System, Charlotte, NC
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■ CLINICAL COMMENTARY
When diagnosing PID, a clinician 
must have a high index of suspicion
PID is a difficult diagnosis to make, without
clear-cut diagnostic guideposts. The sequelae
of PID can be so serious that clinicians must
not miss this diagnosis. If results of all 4 tests
described above are negative, this can reliably
rule out the diagnosis. 
Unfortunately, no set of tests can reliably
confirm the diagnosis in all cases. The tradi-
tional triad of lower abdominal pain, cervical
motion tenderness, and adnexal pain are still
taught as the classic findings for diagnosing
PID. The clinician must also have a high index
of suspicion, particularly with teen-agers with
abdominal pain, and when the pain is indolent
and lingering.
Nonetheless, a recent study concludes there
is insufficient evidence to support existing
clinical diagnostic criteria and recommends
that the clinical criteria for PID be redefined.
In a group of patients with laparoscopically
confirmed PID, no variable (abnormal vaginal
discharge, fever >38°C, vomiting, menstrual
irregularity, ongoing bleeding, symptoms of
urethritis, rectal temperature >38°C, marked
tenderness of pelvic organs on bimanual
examination, adnexal mass, and ESR >15
mm) reliably predicted the disease, and found,
rather, that most had low specificity and sen-
sitivity. The chance of having PID based on the
presence of lower abdominal pain was 79%.
Three variables predicted 65% of the cases of
PID: elevated ESR, fever, and adnexal tender-
ness. When evaluating patients for admission,
some authors add “the desire to bear children”
to the standard admission criteria, which
include severity of sickness, pregnancy, possi-
ble need for surgical intervention, lack of
response to oral medications, or immuno-
suppression.
Ellen Beck, MD, University of California–San Diego
